PCI Biotech Holding ASA (PCIB.OL)

PCI Biotech Holding ASA (PCIB.OL) — VMCI valuation read

Across 120 indicators, PCI Biotech Holding ASA (PCIB.OL) lands at VMCI 50/100. The broad-market sample median is 50, so the 1-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on PCIB.OL in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, PCIB.OL trades at 21.0x earnings, 17% above the sector median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 9.0% trails the sector median (10.0%) by 1.0pp. On Risk, net debt to EBITDA of -2.1x leaves covenant headroom for PCIB.OL on the trailing balance sheet.

PCIB.OL fell 0.4% over the trailing 7 days, with a -4.7% read on a 30-day basis.